SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION

by DIACOUSTIC MEDICAL DEVICES (PTY)

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

These tools are adjacent rather than direct competitors, as they address distinct clinical needs within cardiology. SensiCardiac Mobi aids in the real-time diagnosis of heart murmurs using acoustic signals, while Tempus ECG-AF predicts the 12-month risk of atrial fibrillation in specific elderly patients based on 12-lead ECG analysis. Therefore, the choice depends on whether the clinical focus is on immediate murmur assessment or future AF risk prediction.

Choose SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION if…

Choose SensiCardiac Mobi if your primary need is to quickly and accurately differentiate between physiological and pathological heart murmurs during a patient's physical examination. This tool is ideal for clinicians across specialties, including pediatrics, who require AI-powered decision support to analyze acoustic heart signals in real-time and guide further diagnostic steps.

View SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your goal is to proactively identify older adult patients (65+) at increased risk of developing new-onset atrial fibrillation within the next year, utilizing their standard 12-lead ECG data. This solution is best suited for integrating into existing cardiology workflows to flag high-risk individuals for earlier follow-up and preventative management, rather than immediate diagnostic assessment of existing symptoms.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION	Tempus ECG-AF
Pricing	Contact for pricing	Contact vendor
Deployment	Hosted server environment (Linux OS) with a mobile application interface	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION

Tool A, SensiCardiac Mobi, offers a mobile application interface for real-time heart sound analysis at the point of care, requiring only a compatible electronic stethoscope. This direct, interactive approach on a mobile device likely provides a more immediate and hands-on user experience for clinicians during patient examinations compared to Tool B's system integration.

Clinical Value

Tie

Both tools offer significant clinical value, are FDA-cleared, and address critical areas in cardiology. Tool A aids in the immediate diagnosis of heart murmurs, a common clinical challenge, while Tool B provides predictive risk assessment for Atrial Fibrillation, a serious condition, leveraging a large training dataset. Their value propositions are strong but target different clinical needs and workflows.

Pricing & Value

Tempus ECG-AF

Tool B, Tempus ECG-AF, clearly outlines CMS reimbursement availability with specific CPT codes and a Medicare rate, which significantly enhances its financial value proposition for healthcare providers. Tool A, SensiCardiac Mobi, only states 'contact for pricing' with no public details or reimbursement information, making its financial value less transparent.

Enterprise Readiness

Tempus ECG-AF

Both tools are HIPAA compliant and have BAAs, indicating a foundational readiness for enterprise use. However, Tool B explicitly states it is a 'software solution, integrated into healthcare facility systems,' suggesting a more robust and seamless enterprise-level deployment strategy compared to Tool A's 'hosted server environment' with a mobile application interface, which might imply a more departmental or standalone implementation.

Innovation

SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION

Tool A, SensiCardiac Mobi, demonstrates a higher degree of innovation by applying AI to real-time acoustic heart signal analysis via a mobile application and electronic stethoscope, bringing advanced diagnostics directly to the point of care for a traditional diagnostic method. While Tool B's predictive analytics for AF risk from standard ECGs is valuable, the integration of AI with mobile auscultation feels more novel in its approach to clinical practice.

Support & Docs

Tie

Neither the provided structured facts nor general web searches yielded specific, comparable information regarding the availability, quality, or scope of support and documentation for either SensiCardiac Mobi or Tempus ECG-AF. Without this crucial information, it is not possible to distinguish between the two tools on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION	Tempus ECG-AF
Tool Name	SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION	Tempus ECG-AF
Company	DIACOUSTIC MEDICAL DEVICES (PTY)	Tempus AI, Inc.
Description	FDA-cleared AI-powered mobile application that assists physicians in diagnosing heart murmurs by analyzing acoustic heart signals from an electronic stethoscope to differentiate between physiological and pathological sounds.	FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up.
Key Functionality	Analyzes acoustic heart signals to differentiate between physiological and pathological heart murmurs.	Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
Target Patient Population	Not specified	Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.
Required Hardware/Input	Compatible electronic stethoscope (user-provided), Mobile application for data capture and display (e.g., iPhone 4S or later)	FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems

Videos

Demos, reviews, and walkthroughs featuring SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into a physician's existing clinical workflow?

SensiCardiac Mobi is a mobile application that acquires and records acoustic heart signals using a user-provided electronic stethoscope, functioning as decision support to complement physician assessment of heart murmurs. Tempus ECG-AF is a software solution designed to integrate into healthcare facility systems, analyzing 12-lead ECG recordings to identify patients at risk of developing atrial fibrillation.

What specific clinical conditions and patient populations are best served by each tool?

SensiCardiac Mobi assists in diagnosing heart murmurs by distinguishing between physiological and pathological sounds, applicable across specialties like Cardiology, Internal Medicine, and Pediatrics. Tempus ECG-AF is intended for patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, to identify those at increased risk of developing atrial fibrillation/flutter within the next 12 months.

What kind of data input is required for each tool, and what actionable insights do they provide?

SensiCardiac Mobi requires acoustic heart signals recorded at four main auscultation positions via a compatible electronic stethoscope, providing analysis to identify S1, S2, and suspected murmurs. Tempus ECG-AF analyzes 12-lead ECG recordings from compatible GE Medical Systems and Philips Medical Systems devices, providing results that indicate an increased or no increased risk of new onset AF within 12 months.

What is the anticipated depth of integration with existing Electronic Health Record (EHR) systems for each tool?

Tempus ECG-AF is designed to work with existing ECG platforms and EHRs to enable advanced AI deployment and insights within clinical workflows, including patient filtering based on EHR data. SensiCardiac Mobi functions as a mobile application for data capture and display, which may suggest a more standalone operation or require manual data transfer to EHRs.

What is the anticipated learning curve for physicians and staff to effectively use each tool?

SensiCardiac Mobi, as a mobile application utilizing an electronic stethoscope, is likely to have a relatively straightforward learning curve for physicians familiar with auscultation. Tempus ECG-AF, being an integrated software solution, requires clinicians to interpret its risk assessments in conjunction with other diagnostic information and clinical history.

How do these tools support audit trails and the inclusion of their findings in patient records?

SensiCardiac Mobi acquires and records acoustic heart signals, implying these recordings and their analysis can contribute to a patient's record. Tempus ECG-AF's results are intended to be interpreted in conjunction with other diagnostic information and clinical history, suggesting their integration into the patient's comprehensive medical record.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION or Tempus ECG-AF

Backers

Who funded each tool's parent company.